Sector News

Integra LifeSciences Names Keith Valentine as Chief Executive Officer of SeaSpine

May 1, 2015
Life sciences
(GLOBE NEWSWIRE via COMTEX) – Integra LifeSciences Holdings Corporation IART, +10.82% today announced the appointment, effective May 1, 2015, of Keith Valentine as Chief Executive Officer of SeaSpine Holdings Corporation, which will be an independent, publicly traded company following the completion of its spin-off from Integra. SeaSpine, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, located in Vista, CA, has a comprehensive portfolio of orthobiologics and spinal fusion hardware solutions.
“With more than 20 years of experience in the orthopedic industry and an outstanding track record of success, Keith’s proven leadership skills will drive growth and innovation at SeaSpine,” said Peter Arduini, Integra’s President and Chief Executive Officer. 
Prior to joining SeaSpine, Mr. Valentine served as President and Chief Operating Officer of NuVasive, Inc. from January 2007 to January 2015 and as President from December 2004 to January 2007, prior to which he served in various senior executive roles in Marketing, Development and Operations since joining NuVasive in 2001. Previously, Mr. Valentine served as Vice President of Marketing at ORATEC Interventions, Inc., a medical device company acquired by Smith & Nephew PLC, and spent eight years in various roles with Medtronic Sofamor Danek including, Vice President of Marketing for the Rods Division and Group Director for the BMP Biologics program, the Interbody Sales Development Effort, and International Sales and Marketing.
“I am thrilled to have the opportunity to lead SeaSpine following the spin-off from Integra,” said Mr. Valentine. “SeaSpine has the ability to leverage its leading orthobiologics products and broad spinal fusion hardware portfolio, as well as invest in a pipeline of differentiated products to drive growth. I look forward to working with our customers, our strong management team, employees, and our future investors in the coming weeks and months.”
John Bostjancic was also recently named Chief Financial Officer of SeaSpine. Mr. Bostjancic has been Acting CFO of SeaSpine since December 2014. He was most recently a Senior Vice President of Global Supply Chain at Integra from February 2012 to November 2014. From 2008 to January 2012, Mr. Bostjancic was Senior Vice President of Financial Planning and Analysis. He joined Integra in 1999 and held roles of increasing responsibility in the finance organization, including Corporate Controller from 2003 to 2006. Previously, Mr. Bostjancic worked at Merck & Co., Inc. and PricewaterhouseCoopers.
Kirt Stephenson, future Chairman of SeaSpine’s Board of Directors, said, “We are pleased to have a CEO with Keith’s background and track record, as well as a proven financial executive in John Bostjancic. We now have the leadership team in place to lead an independent SeaSpine forward.” 
On November 3, 2014, the Company announced that it plans to spin off its orthobiologics and spinal fusion hardware business into a standalone public company. The spin-off is expected to take the form of a distribution that will be tax-free, except for cash received in lieu of fractional shares, to Integra shareholders of a new publicly traded stock in SeaSpine. The spin-off is expected to be completed in the second half of 2015, subject to certain customary conditions, including declaration by the SEC of the effectiveness of the Form 10, confirmation of the tax-free nature of the transaction and final approval of the spin-off by Integra’s Board of Directors.
Source: Integra LifeSciences

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]